Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Ar...
Elsa Vieira-Sousa, Pedro Alves, Ana Maria Rodrigues et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) dactylitis is associated with an increased risk of erosions and higher disease activity. Dactylitis treatment strategies are however controversial due to the absence of evidence from randomized controlled trials studying dactylitis as a primary outcome. The objective of this trial was to assess the efficacy of golimumab in combination with methotrex...

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Contro...
Philip Mease, Laure Gossec, Laura Coates et. al.

Nov 13th, 2019 - Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of significant inflammatory disease activity’.1,2 Since many patients with PsA may not achieve clinical remission, treatment recommendations recognise minimal or low disease activity as an important alternative treatment t...

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in P...
Philip Mease, Saima Chohan, Ferran J. García Fructuoso et. al.

Nov 13th, 2019 - Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the 24-week efficacy and safety results from a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b TIL study in patients with active PsA (NCT02980692). Methods...

Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos, Laura Coates, Laure Gossec et. al.

Nov 13th, 2019 - Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this s...

Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang, Yu-fei Hao, Sheng-xiao Zhang et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a functional deficiency in suppressing effector T-cells in PsA, absolute quantitative status of peripheral Treg or Th17 cells is still unclear. On the other hand, recent studies have revealed that low-dose I...

Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Timothy Kwok, Justine (Yang) Ye, Daniel Pereira 2 and Dafna Gladman et. al.

Nov 12th, 2019 - Background/Purpose: Evidence thus far on the effect of psoriatic arthritis (PsA) on bone mineral density (BMD) has been inconsistent. There is also insufficient guidance surrounding BMD testing in PsA patients. The purpose of this study was to determine BMD in the PsA population, factors associated with having BMD testing performed, and the effect of PsA clinical activity on BMD. Methods: : Thi...

Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox
Dilek Solmaz, Umut Kalyoncu, Ilaria Tinazzi et. al.

Nov 12th, 2019 - Background/Purpose: Smoking has been shown to be associated with an increased risk of psoriatic arthritis (PsA) in the general population, but there are controversies among patients with psoriasis. We hypothesize that smoking is a risk factor for axial PsA specifically, similar to axial spondyloarthritis, more than the other PsA phenotypes. Methods: PsArt-ID (Psoriatic Arthritis- International ...

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Eric Toussirot, Francois Aubin, maxime Desmarets et. al.

Nov 12th, 2019 - Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV) risk. Obesity is also a risk factor for the onset of these diseases. Body composition and fat distribution have been rarely evaluated in Pso and PsA. In this study, we aimed to characterize the fat mass...

Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Michaela Koehm, Sarah Ohrndorf, Tanja Rossmanith et. al.

Nov 12th, 2019 - Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the skin manifestation appears usually years before PsA-related symptoms emerge. Up to 30% of Pso patients develop PsA, but there is no clear correlation between disease duration of Pso and PsA development. Therefore, biomarke...

Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis
Remy Pollock, Rohan Machhar, Vinod Chandran 2 and Dafna Gladman et. al.

Nov 12th, 2019 - Background/Purpose: Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, usually after psoriasis onset. A large proportion of individuals with PsA remain undiagnosed. An understanding of how the epigenome changes during the transition to PsA could yield predictive biomarkers and facilitate PsA diagnosis. We hypothesized that DNA met...

Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis
Ana B Arevalo, Faris Haddadin, Gustavo Contreras et. al.

Nov 12th, 2019 - Background/Purpose: Inflammatory joint diseases (IJD) such as psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD) since inflammation plays a pivotal role in the pathogenesis of coronary artery disease (CAD), heart failure (HF) and atrial fibrillation (Afib)1. Ischemic heart disease and HF are the main causes of the increased and premature mortality among patients wi...

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai, Rebecca Manno, Jamie Perin et. al.

Nov 12th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using a T-score metric referenced to the general population, and has not been used in PsA before. The objective was to assess construct validity of the PROMIS Profile29 in PsA. Methods: Participants with PsA were followed eve...

Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell, Elaine Karis, Kelly Gavigan et. al.

Nov 12th, 2019 - Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations. Despite the well-known benefits of MTX, it is associated with a number of potential side effects and tolerability issues including nausea and fatigue, gastrointestinal toxicity, skin reactions, headaches, mouth sor...

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries
Penelope Palominos, Laura Coates, Charles Kohem et. al.

Nov 12th, 2019 - Background/Purpose: Sleep quality is diminished in patients with psoriatic arthritis (PsA) and close to 40% of PsA patients consider sleep impairment a priority domain.This work analyzed determinants of impaired sleep in patients with PsA. Methods: This was a cross-sectional analysis of an observational study (ReFlap, NCT03119805), which included adult patients with definite PsA with ≥ 2 years ...

MDA Versus DAPSA: Applicability in a Real World
rafaela Gonçalves, Lays Martins, henrique mariz et. al.

Nov 12th, 2019 - Background/Purpose: Background/Purpose: Psoriatic arthritis (PsA) is a progressive, chronic, and potentially irreversible inflammatory disorder. Systematic clinical follow-up of PsA patients is necessary to maintain and adjusting the proposed therapy. There are two different disease activity composite index suggested by Treat To Target (1). MDA (2) defines a state of illness and includes joint ...

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Clara Pérez-Velásquez, Oihane Ibarguengoitia-Barrena, David Montero-Seisdedos et. al.

Nov 12th, 2019 - Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There are published data about different models, activity data and patient satisfaction in this kind os unit. To evaluate its effectiveness, we also need to know the clinical results of patients with PsA who visit the...

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie, Mei Liu, Meghan Glynn et. al.

Nov 12th, 2019 - Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry, a prospective, US-based, observational cohort study, collects real-world data on PsA patient characteristics and treatment, including oligoarthritis. This analysis characterized patient demographics, clinical character...

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Ana-Maria Orbai, Jamie Perin, Albert W Wu et. al.

Nov 12th, 2019 - Background/Purpose: Pain, physical function and fatigue are outcomes reported as having the greatest importance to people with psoriatic arthritis (PsA)1,2. We assessed these outcomes in participants in a longitudinal PsA study using Patient Reported Outcomes Measurement Information System (PROMIS) measures, which have not been used before in PsA, concomitantly with measures of PsA-specific dis...

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman, Samrachana Adhikari, Deborah Ramirez et. al.

Nov 12th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease affecting skin, joints, and other domains. While psychiatric diseases (i.e., depression and anxiety) are known comorbidities, little is known about their impact on disease severity and patient reported outcomes (PROs). The objective of this study was to characterize the prevalence of psychiatric comorbidities i...

Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco, Sandra Garcet, Mustimbo roberts et. al.

Nov 12th, 2019 - Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on psoriatic inflammation at a molecular level has not been determined. Methods: 40 patients received ABA and 38 received PBO in this substudy of a 24 week, Phase 3, randomized, double blind, placebo (PBO) control...